Acute kidney injury (AKI) is frequently observed after cardiac surgery (CS) with cardiopulmonary bypass (CPB). Multiple mechanisms underlie this phenomenon, including CPB-dependent haemolysis. Haemoglobin is released during haemolysis, and free haemoglobin (frHb) causes tubular cell injury after exceeding the binding capacity of haptoglobin (Hp). The objective of this study was to investigate the influence of perioperative changes in frHb and Hp levels on the incidence of CS-associated (CSA) AKI. After receiving local ethics committee approval and obtaining informed consent from our patients, we analysed the data pertaining to 154 patients undergoing CPB surgery. We recorded frHb and Hp concentrations pre-, intra-and postoperatively and defined AKI using the Kidney Disease Improving Global Outcomes (KDIGO) classification. We observed that frHb levels increased significantly during surgery and then decreased at ten hours thereafter and that Hp levels decreased during surgery and remained at low levels until the first postoperative day. We noted a moderate negative correlation between frHb and Hp levels. AKI was identified in 45.5% of patients; however, there was no significant difference in frHb or Hp levels between patients with and without AKI. We did not observe a relationship between frHb or Hp levels and CSA AKI and thus could not confirm the hypothesis that patients with higher baseline Hp concentrations experience a lower incidence of AKI than patients with lower baseline Hp concentrations.
Introduction
Postoperative acute kidney injury (AKI) is frequently observed after cardiac surgery (CS) with cardiopulmonary bypass (CPB) 1, 2 . This severe complication is associated with adverse patient outcomes and has extensive medical and economic consequences 3 . AKI has been reported in 25% of patients after CS 4 , with up to 5% requiring renal replacement therapy (RRT) 5 . CS with CPB is associated with a postoperative mortality rate of 2 to 8%. In the event of AKI, however, this mortality rate increases exponentially 6, 7 .
Multiple mechanisms underlie CS-associated (CSA) AKI, including ischaemia-reperfusion injury, perioperative haemodynamic instability, renal blood flow impairment, CPBinduced inflammatory pathway activation, and haemolysis 5, 8 . Haemolysis is induced during CPB via erythrocyte mechanical destruction caused by contact with the bypass circuit surface, high blood flow and pressure conditions, and cardiotomy suctioning 5, 9 , resulting in haemoglobin release into the plasma, where it binds mainly to haptoglobin (Hp) to form complexes that inhibit haemoglobin excretion through the glomerulus 10, 11 . After exceeding the binding capacity of Hp, free haemoglobin (frHb) passes through the glomerulus 10, 12 , resulting in tubular obstruction caused by methaemoglobin casts, as well as tubular cell necrosis 13 . Free haemoglobin also scavenges endothelium-derived nitric oxide, causing vasoconstriction and decreased blood flow, which leads to end-organ injury [14] [15] [16] .
The objective of the present pilot study was to investigate the influence of perioperative changes in frHb and Hp levels on the incidence of CSA AKI. We tested the hypothesis that patients who develop postoperative AKI exhibit higher frHb concentrations and therefore exhibit lower Hp concentrations than patients without AKI. We also investigated whether baseline Hp concentrations exert preventative effects on AKI.
Methods
This prospective observational pilot trial was approved by the ethics committee of the Medical University of Goettingen (registration number: 17/2/13) and is registered at the German Clinical Trials Register under the following number (DRKS): DRKS000054 57.
The recruitment period lasted from July 2013 to April 2014. We included patients older than 18 years who provided informed consent and underwent (elective and non-elective) coronary artery bypass grafting (CABG) surgery with CPB at the University Hospital of Goettingen. Patients who underwent simultaneous valve or vascular-non-coronary artery procedures, as well as patients with pre-existing chronic renal failure requiring RRT or cardiac failure requiring extracorporeal membrane oxygenation, were excluded from this study.
CABG surgery was performed via median sternotomy. Before cannulation, 300 IU/kg body weight of unfractionated heparin was administered to each patient. CPB (Maquet Jostra HL20, SOMA Technology, Inc., Bloomfield, USA) was established using a centrifugal pump and a membrane oxygenator (Capiox® FX25E/R, Terumo, Ann Arbor, MI, USA). Myocardial protection was performed using Buckberg blood cardioplegia solution. Two cardiotomy suction lines were used. After CPB termination, unfractionated heparin was antagonised using protamine chloride, and the residual pump blood in the CPB circuit reservoir was re-transfused, as described in a previous trial 17 . Furthermore, all patients received a standardised perioperative intravenous (IV) sodium bicarbonate infusion (0.15 mmol/kg/hour), which was initiated intraoperatively and continued for 24 hours postoperatively, based on the recommendations of a national position paper 18 .
Biometrics
Information regarding the following biometric characteristics, comorbidities and surgical factors was collected: sex, age, body mass index, left ventricular ejection fraction (EF), congestive heart failure/New York Heart Association-classification (CHF), chronic obstructive pulmonary disease (COPD), insulin-dependent diabetes mellitus (IDDM), preoperative intra-aortic balloon pump (IABP) use, and preoperative serum creatinine concentrations. We also reported information regarding whether CABG surgery was performed as a primary or repeat procedure or as an elective or emergency procedure, as well as information regarding CPB duration, aortic crossclamping (ACC) time, and blood and coagulation product use. Individual risk stratification was performed using the EuroSCORE 19 and the clinical predictive score developed by Thakar et al 6 , which demonstrated an acceptable ability to predict the risk of AKI 20, 21 .
Free haemoglobin and haptoglobin
We recorded frHb and Hp concentrations at the following five measurement points: • frHb1, Hp1: baseline, before CPB • frHb2, Hp2: immediately after starting CPB • frHb3, Hp3: 15 minutes after protamine administration (after CPB termination) • frHb4, Hp4: 10 hours after baseline • frHb5, Hp5: 0500 hours on the first postoperative day Immunoturbidimetric tests (ARCHITECT, Abbott Clinical Chemistry, Abbott Park, IL, USA) were used. A 3-wavelengthmeasuring method (Photometer 5010V5+, Robert Riele KG, Berlin, Germany) was used to quantify frHb1-3 concentrations, and a 7-wavelength-measuring method (Photometer ARCHITECT, Abbott Clinical Chemistry, Abbott Park, IL, USA) was used to quantify frHb4-5 concentrations.
Concentrations below the identifiable threshold were displayed as <0.03 g/l and regarded as 0.03 g/l for statistical analyses.
Outcome parameters
Postoperatively, the severity of AKI was evaluated using the Kidney Disease Improving Global Outcomes (KDIGO) classification 22 . Daily KDIGO stages were determined based on patient diuresis rates (recorded by intensive care unit [ICU] nurses, who were blinded to the frHb and Hp concentration results) and serum creatinine concentrations (determined by central laboratory medical-laboratory assistants, who were not aware of the study). We included the maximum KDIGO stage achieved by each patient during the time period ranging from the day of surgery to the fifth postoperative day in our analysis. The cohort was organised into the following groups for analysis: KDIGO 0 (without AKI) and KDIGO ≥1 (with AKI). Additionally, length of hospitalisation, length of stay in the ICU, and in-hospital mortality were recorded as secondary outcome parameters.
Statistics
Biometric analyses and AKI risk stratification were performed using the Mann-Whitney U, chi-squared and Fisher's exact tests, as well as logistic regression, which were performed using Statistica (Version 10, 1984-2011, 
Results
After exclusions, 154 patients remained in the analysis. Their biometric characteristics, comorbidities and intraoperative data are presented in Table 1 . Individual preoperative AKI risk stratification scores ranged from 0 to 6 Thakar points ( Table 2) .
The baseline frHb concentration (frHb1) was 0.09 g/l (IQR 0.05-0.17). The frHb concentration increased to a median of 0.22 g/l during CPB before peaking at a median of 0.39 g/l (IQR 0.26-0.52) at 15 minutes after CPB (frHb3), decreasing to a median of 0.09 g/l (IQR 0.06-0.15)-similar to its original level-at ten hours after baseline (frHb4) and then decreasing to a median of 0.06 g/l (IQR 0.05-0.09) the following morning (frHb5) (Figure 1 ). Significant differences in the frHb concentration were noted among all of these measurement points (P=0.0001 to 0.02).
The median pre-surgery Hp concentration was 1.36 g/l (Hp1). The Hp concentration decreased to 0.75 g/l (Hp2) and 0.41 g/l (Hp3) during surgery and reached its nadir at 10 hours after baseline (0.12 g/l) before beginning to increase the following morning (0.22 g/l, IQR 0.09-0.41) ( Figure 2 ). Significant differences in the Hp concentration were noted among all these measurement points (P <0.0001). 
Correlation between haptoglobin and free haemoglobin levels
To analyse the relationship between frHb and Hp concentrations, we determined the correlation coefficients (r) and the r² for each measurement point. We observed a moderate negative correlation between frHb and Hp during the intraoperative period ( Figure 3 ) but noted only a low negative correlation between frHb and Hp at baseline and postoperatively ( Table 3 ). Power analysis demonstrated power values of 97.6% and 82.1% (alpha 0.05) for the above correlations at the two intraoperative measurement points.
Outcome parameters
AKI was identified in 45.5% of the 154 patients. In particular, KDIGO 1 was identified more frequently (n=56) than KDIGO 2 (n=12), and KDIGO 3 was identified very rarely (n=2) ( Table 4 ). Comparisons regarding in-hospital mortality and length of stay (for both hospitalisation and intensive care) demonstrated that patients with AKI exhibited significant higher in-hospital mortality and remained hospitalised longer than patients without AKI (P=0.0012 and P <0.0001). The median lengths of stay in the hospital and ICU were 13 days and 10 days and four days and one day among patients with and without AKI, respectively. The in-hospital mortality rate was 2.6% (n=4) and only occurred in patients with acute kidney injury (P=0.0407, Table 5 ).
After dividing the study cohort into patients with (KDIGO Table 3 Correlation of free haemoglobin and haptoglobin at timepoints 1-5. We determined the correlation coefficients (=r) and the determination coefficients (=r²) for each measurement point. We observed a moderate negative correlation between frHb and Hp concentrations during the intraoperative period but noted only a low negative correlation between frHb and Hp concentrations at baseline and postoperatively. FrHb, free haemoglobin; Hp, haptoglobin. Timepoints: 1, baseline; 2, at start of cardiopulmonary bypass; 3, 15 minutes after protamine administration; 4, 10 hours after baseline; 5, following day. 
1-3) and without AKI (KDIGO 0)
, we noted no significant differences in frHb or Hp concentrations between the two groups ( Table 6 ).
Discussion
The aim of this study was to investigate the influence of perioperative changes in frHb and Hp levels on the incidence of CSA AKI. Our results indicated that there was little interindividual variation in baseline Hp concentrations. Hp concentrations decreased during CS, reaching their minimum level within several hours after surgery and remaining at this low level until the following day, and frHb concentrations began to rise immediately during CPB, increasing by a factor of five compared with baseline intraoperatively. FrHb concentrations reached their maximum value after Table 6 Median values of free haemoglobin and haptoglobin in patients without and with acute kidney injury CPB termination before returning to their normal range at ten hours thereafter. These findings indicate that the intraoperative courses of Hp and frHb were negatively correlated with each other. CSA AKI was identified in 45.5% of patients. Contrary to our expectations, we noted no association among frHb concentrations, Hp concentrations and AKI occurrence. Thus, the hypothesis that patients who develop postoperative AKI exhibit higher frHb concentrations and lower Hp concentrations than patients without AKI was not confirmed.
Plasma free haemoglobin
Data demonstrating an association between increased frHb concentrations and AKI after CPB have recently been published 23, 24 . Another study noted a correlation among frHb levels, oxidative stress and postoperative increases in creatinine levels 25 . Nephrotoxicity is known to manifest involving CPB can be beneficial for patients at risk for AKI, it is important to consider the changes in frHb and Hp concentrations that occur during CPB. We observed that Hp concentrations remained at very low levels after CPB until the first postoperative day, whereas frHb concentrations had already returned to their normal range, indicating that the capacity of Hp to bind Hb remained exhausted. Thus, exogenous Hp supplementation may prevent postoperative frHb urinary excretion, especially in patients with extremely high frHb concentrations. In particular, early Hp supplementation may be a reasonable strategy for scavenging excess frHb during its intraoperative peak period. It can be assumed that the faster frHb concentrations return to their normal range, the less time that tubular cells are exposed to increased frHb concentrations, resulting in less severe cellular injury. Administering exogenous Hp before CPB as a means of completely scavenging frHb to reduce the incidence of CSA AKI may also be possible.
Single case reports and a few pilot studies regarding Hp supplementation as a means of combating haemolysis in different settings, including CPB, massive transfusions, thermal injuries and haemolysis-associated diseases, have been published. In these studies, 2000 to 8000 IE of plasmaderived Hp products were administered. The results of these studies suggest that Hp has a strong potential to neutralise the adverse effects of frHb 11, 12, 29, 30, [34] [35] [36] [37] [38] [39] [40] [41] [42] .
Risk profile of the patient cohort and sodium bicarbonate therapy
Including CABG-only patients in this study resulted in a lower AKI risk profile in this investigation than in those regarding valve and combined procedures 6, 43 ; 76% of patients exhibited scores of 0-2 Thakar points (and were accordingly classified as having a low risk of AKI requiring RRT). Patients who developed AKI were mainly classified as KDIGO 1; not even 10% of patients were classified as KDIGO 2 and 3. Therefore, it was not possible to estimate the potential influence of frHb and Hp concentrations on AKI (mostly KDIGO 1) in this study cohort. However, the influence of frHb and Hp on the incidence of AKI may be detectable in studies including more patients classified as KDIGO 2 or 3.
As stated above, low numbers of patients were classified as KDIGO 2 or 3. These results may be attributable to IV infusions of sodium bicarbonate, which causes urinary alkalinisation and may therefore play a role in preventing haemoglobin-associated pigment nephropathy and AKI, especially in CABG patients 8, 24 . Urinary alkalinisation reduces haemoglobin endocytosis, thereby protecting against proximal tubular cell necrosis, preventing tubular obstruction (by reducing the amounts of haemoglobin that are converted to methaemoglobin), and protecting against oxidant injury by limiting the production of free radicals and other reactive oxygen species 5, 15 . Several recent trials have investigated the effects of sodium bicarbonate and reported controversial as haemoglobinuria and myoglobinuria, both of which are associated with a condition known as pigment nephropathy. Myoglobin and haemoglobin have similar chemical core structures, which comprise haem proteins. Both molecules are able to release free iron, which can exert nephrotoxic effects 5, 26, 27 ; therefore, both molecules can be expected to exert similar effects with respect to the pathogenesis of AKI, and frHb can be regarded as a nephrotoxin comparable to the more widely appreciated myoglobin.
It is unknown whether increased exposure of the tubular system to frHb causes CSA AKI, or, more likely, if increased exposure of the tubular system to peak frHb concentrations causes CSA AKI. After CPB termination, patients received residual CPB reservoir pump blood, which contains high quantities of frHb. However, a previous trial performed in our department demonstrated that this re-transfusion does not increase patient frHb levels 17 , as we did not observe elevated peak levels. Moreover, we observed that the median CPB frHb concentration noted during the present study was considerably lower than the concentrations reported in the literature, which ranged from 0.46 ± 0.25 and 0.55 ± 0.27 g/l (depending on whether various suction devices were used) 28 and 0.65 g/l 29 and 1.2 ± 0.73 g/l 30 to 1.04 ± 0.36 g/l (patients without AKI) and 2.89 ± 0.38 g/l (patients with AKI) 25 . FrHb levels are dependent on the intensities of the stresses that erythrocytes are subjected to as a result of contact with the surfaces of the pump and bypass circuit (boundary layer of the oxygenator, tubing, and filters), cross-sectional areas, and cardiotomy suctioning, all of which deteriorate as a result of CPB prolongation, high pressures, and high flow conditions 5, 9, 25, 31, 32 .
We observed that the frHb concentration had already returned to its normal range within several hours after surgery, indicating that frHb is perpetually excreted by the tubular system (in addition to being bound by Hp and endocytosed by the reticulo-endothelial system 33 ). However, we noted no differences in the rates at which frHb levels increased or normalised between patients with and without AKI. Therefore, it was not possible to specify an frHb cut-off point above which frHb is associated with AKI.
Haptoglobin
We investigated whether baseline Hp concentrations had an influence on the incidence of AKI. We anticipated that patients with higher baseline Hp concentrations would experience a lower incidence of AKI than patients with lower baseline Hp concentrations-as the former group of patients would exhibit a higher total binding capacity for Hb and thus be better protected against frHb-induced nephrotoxicity than the latter group of patients-a hypothesis that was not supported by our data. Regarding the excessive quantity of frHb that accrued during CPB, the difference in Hp baseline concentrations of 1 or 2 g/l remained small.
Regarding whether Hp supplementation during CS results 8, [44] [45] [46] [47] . In a previous trial conducted by our department, we noted a significantly lower incidence of AKI in CS patients who received sodium bicarbonate than in patients who did not receive sodium bicarbonate 24 . Therefore, in clinical practice, we administer sodium bicarbonate to prevent CSA AKI, and its administration is considered a standard of care at our institution. One can assume that a cohort at higher risk for AKI and, particularly, exhibiting a greater level of haemolysis will be characterised by the presence of significant differences in frHb and Hp concentrations between patients with and without AKI. It is also possible that differences in the incidence of AKI-which is dependent on frHb and Hp levels-may become more apparent without the use of sodium bicarbonate. However, CSA AKI has multiple causes (haemodynamic instability and inflammation, in addition to haemolysis) 5 , and AKI worsens in parallel with increases in the numbers of risk factors 8, 24 . Thus, preventing pigment nephropathy via Hp supplementation, which addresses only one mechanism underlying AKI development, may still be less effective in patients with more AKI risk factors.
In addition to analysing physiological endogenous Hp levels, future trials should also evaluate the use of prophylactic exogenous Hp under experimental conditions during CPB, preferably using animal models.
Study limitations
This was an observational study; therefore, randomisation was not performed, nor was it even reasonable. We observed and analysed frHb and Hp concentrations during CPB and found no association among frHb concentrations, Hp concentrations and CSA AKI. Our conclusions were based on these findings. We did not analyse the incidence of AKI in the absence of frHb after exogenous Hp administration. Future trials may address this issue.
Conclusion
We found that frHb concentrations increased significantly during CPB before decreasing at 10 hours thereafter, whereas Hp concentrations decreased intraoperatively and remained at a low level until the first postoperative day. We noted a moderate negative correlation between frHb and Hp concentrations during the intraoperative period. However, we observed no significant differences in frHb or Hp concentrations between patients with and without AKI. Therefore, the hypothesis that patients with higher baseline Hp concentrations experience a lower incidence of AKI than patients with lower baseline Hp concentrations was not confirmed. Since our study results indicated that there was no association among frHb, Hp and AKI, our data do not support the idea that preventing frHb increases via exogenous Hp supplementation can avert AKI in CABG surgery.
